BackAscentage Pharma Group International Overview

Ascentage Pharma Group International Total Assets

Latest total assets for ASPHF: $3.2B.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$3.24B
↑ 6.38% YoYΔ $194.49M vs prior year quarter

Peer trimmed avg / median

Loading

Ascentage Pharma Group International Total Assets History

Loading

Ascentage Pharma Group International vs. peers: Total Assets Comparison

Loading

Ascentage Pharma Group International Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Ascentage Pharma Group International (ASPHF) FAQ

Ascentage Pharma Group International posts a total assets of $3.2B as of June 2026. That compares with $3B in the prior-year period — up 6.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Ascentage Pharma Group International's total assets was $3B. The latest reading is $3.2B — a 6.4% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Total Assets is one piece of Ascentage Pharma Group International's financial statement story. At $3.2B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ASPHF's total assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Ascentage Pharma Group International's other metric pages and overview cover the third.

Judging Ascentage Pharma Group International against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total assets easier to interpret. Start with $3.2B here, then scan peer and history charts to see if the gap is persistent.